Publicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (10)

2020

  1. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565

2018

  1. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319

2015

  1. Enhancing T cell performance against cancer in combination treatment strategies

    Cancer Drug Discovery and Development (Humana Press Inc.), pp. 245-258

  2. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice

    Cancer Research, Vol. 75, Núm. 17, pp. 3466-3478

  3. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors

    Clinical Chemistry, Vol. 61, Núm. 1, pp. 297-304

2014

  1. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins

    Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707

2012

  1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

2011

  1. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients

    Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142

  2. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

    International Journal of Cancer, Vol. 129, Núm. 2, pp. 374-386

2004

  1. ERK 1/2 is activated in non-small-cell lung cancer and associated with advanced tumours

    British Journal of Cancer, Vol. 90, Núm. 5, pp. 1047-1052